亚宝药业集团股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告

Group 1 - The company has approved a share repurchase plan at the 2024 annual general meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [1] - The repurchase will be conducted through centralized bidding and aims to cancel all repurchased shares, thereby reducing the registered capital of the company [1] - The repurchase period is set for a maximum of 6 months from the date of approval by the shareholders' meeting, with funding sourced from the company's own funds and self-raised funds [1] Group 2 - As of July 10, 2025, the company has repurchased 200,000 shares, representing 0.03% of the total share capital, at a maximum and minimum transaction price of RMB 6.30 per share, totaling RMB 1,260,000 (excluding transaction fees) [1] - The repurchase is in compliance with relevant laws and regulations, as well as the company's repurchase plan [1] - The company will continue to make repurchase decisions based on market conditions and fulfill information disclosure obligations in a timely manner [2]